A 47-year-old man with acute myeloblastic leukemia (AML) posed. 15 Thus, HHV-6 reactivation is a crucial issue for sucdeveloped angioimmunoblastic lymphadenopathy with dysprocessful treatment in immunocompromised patients.
/l with 63.0% blasts. Serum blood chemistry was normal. The bone marrow was hypercellular with 89.2% myeloblasts Introduction consistent with a diagnosis of AML (FAB classification M1). The leukemic cells contained t(8;21)(q22;q22) chromosome Human herpesvirus 6 (HHV-6) is the causative agent of exanabnormality. The patient was treated with chemotherapy of them subitum and febrile illnesses in early childhood.
1,2 The idarubicin and cytarabine, which resulted in disappearance of primary HHV-6 infection in seronegative adults has been leukemic cells in the bone marrow. During a leukopenic perrelated to various clinical manifestations, such as chronic iod following chemotherapy, he suffered from pneumonia and fatigue syndrome, necrotizing lymphadenitis, mononucleosispericarditis. Temporal drainage for progressively growing perilike syndrome, and acute hepatitis. [3] [4] [5] [6] As with other herpescardial effusion was necessitated. Cytological examination viruses, HHV-6 is likely to remain latent in the host. A possible revealed the presence of lymphocytes and neutrophils, but no site of latent virus has been identified in salivary glands and infiltration of the leukemic cells was observed. Repeated bacmonocytes/macrophages. 7, 8 HHV-6 can be reactivated during terial, fungal, tuberculous, and routine viological cultures immunosuppression, such as in patients with human immunorevealed no pathogens. After a prolonged leukopenic period deficiency virus and transplant recipients. [9] [10] [11] Complications (leukocyte count Ͻ10 9 /l) for 4 weeks, hemopoietic recovery include interstitial pneumonitis, encephalitis, and fulminant without regrowth of the leukemic cells was achieved. Howhepatitis, that are often life-threatening. [12] [13] [14] Furthermore, a ever, fever persisted with no response to anti-bacterial and bone marrow suppressive role for HHV-6 has been proanti-fungal agents, and generalized skin rash appeared. At that time, there was no evidence of lymphadenopathy. In November 1995, thrombocytopenia gradually developed. Subsequently, lymphadenopathy was first noted in the neck, and protein was elevated and the maximal level at 9.7 g/dl was tures were incubated at 94°C for 3 min for denaturation followed by 35 cycles of 94°C for 1 min, 57°C for 1 min, and achieved in mid-December 1995. Serum protein electrophoresis showed polyclonal hypergammaglobulinemia with 72°C for 1 min. A terminal extension of 72°C for 5 min was performed after completion of the 35 cycles. A total of 20% elevated serum IgG of 5940 mg/dl and serum IgM of 1340 mg/ml. Biopsy of a left inguinal lymph node was diagof the amplification products (10 l) was electrophoresed on a 2% agarose gel followed by ethidium bromide staining and nostic of AILD. At that time, platelet count was down to 15 × 10 9 /l and leukepenia was also observed. Bone marrow aspirvisualization under UV light for the presence of DNA bands of appropriate sizes. Standard recommended procedures were ate showed a mild hypocellularity with an increase of plasmocytoid cells. Combination chemotherapy consisting of cycloperformed in order to avoid false positive results. 25 phosphamide, vincristine and prednisolone began, but the patient's condition failed to improve. He died of fulminant hepatitis in January 1996 when his serum total bilirubin was Results 27.1 mg/dl. The autopsy showed generalized lymphadenopathy with massive mediastinal and abdominal lymphadenoPathologic and immunophenotypic findings pathy, hepatosplenomegaly, and lymphomatous infiltrates involving the liver, bone marrow, lungs, spleen, kidneys and
The inguinal lymph node biopsy specimen obtained in December 1995 displayed diagnostic histologic features of heart. AML was in a complete remission. Retrospectively examined serological titers for HHV-6 on admission were as AILD. The lymph node showed diffuse effacement of nodal architecture with loss of germinal centers. A polymorphous follows: HHV-6 IgG, 1:10 and HHV-6 IgM, Ͻ1:10. Unfortunately, serum taken in a later clinical course was not available cellular infiltrate composed of small to medium lymphocytes, plasma cells, immunoblasts, macrophages, and occasional for HHV-6 antibody testing. neutrophils and eosinophils was observed ( Figure 1 ). Proliferation of high endothelial venules and amorphous eosinophilic interstitial material were present. Clinically shown hypergamMaterials and methods maglobulinemia also supported the diagnosis. Immunohistochemical staining showed a mixed B cell and T cell compoHistologic and immunophenotypic analysis sition. Some immunoblastic cells were positive for T cell marker. The plasma cells were polyclonal in that both and Tissues obtained at biopsy and autopsy were fixed in buffered formalin, embedded in paraffin wax, and stained with hemalight chains were demonstrated. Autopsy showed widespread organ involvement by AILD. toxylin and eosin. Immunophenotypic studies were performed with the use of the monoclonal antibodies L26 (CD20) for B cells (Dakopatts, Glostrup, Denmark) and UCHL-1 (CD3) for T cells (Dakopatts) as well as antibodies for immunoglobulin
Presence of HHV-6 in affected tissues light (, ) chains.
The presence of specific HHV-6 DNA sequences was investigated by PCR. Using a set of primer pair 1, DNA samples from the lymph node biopsy specimen with diagnosis of AILD and
Primers and PCR analysis the AILD-involved tissues of bone marrow, hilar lymph node, lung, liver and spleen were clearly positive for HHV-6 DNA For HHV-6 DNA amplification by polymerase chain reaction (PCR), two sets of primers from different regions of the HHV-( Figure 2 ). HHV-6 DNA was also detected in the pericardial effusion obtained in September 1995 that was presented 3 6 genome were used. The sequences of the first set of primers (designated primer pair 1), derived from a highly conserved months before manifestation of AILD. In contrast, the leukemic cells at admission were negative for HHV-6. The search region shown to encode the major capsid protein, were 5Ј-GCTAGAACGTATTTGCTGCAGAACG-3Ј as sense primer and for Epstein-Barr virus and human herpesvirus 8 by PCR was 5Ј-ATCCGAAACAACTGTCTGACTGGCA-3Ј as antisense primer, generating a 258-base pair (bp) fragment. 23 The second set of primers (primer pair 2), derived from a sequence corresponding to the immediate-early gene, was employed for the determination of HHV-6 variants. 24 The sequences of the primers were 5Ј-TTCTCCAGATGTGCCAGGGAAATCC-3Ј and 5Ј-CATCATTGTTATCGCTTTCACTCTC-3Ј, resuting in generation of 325-bp and 553-bp fragments for type A and type B variant, respectively.
Genomic DNA was extracted from the leukemic bone marrow at admission and pericardial effusion, which were kept frozen until use, as well as from a lymph node biopsy specimen with histologically verified diagnosis of AILD, using the phenol/chloroform extraction technique after proteinase K digestion. We also analyzed genomic DNA from the tissues obtained at autopsy including bone marrow, hilar lymph node, lung, liver and spleen. A total of 100 ng of genomic DNA was amplified in 50 l of PCR buffer (20 mM Tris-HCl, pH 8.4, 50 mM KCl, 1.6 mM MgCl 2 ) with 0.2 mM of each enzyme, and 0.2 M of each pair of primers. Reaction mix-AILD. However, there has been no report as to how this virus is clinically related to the development of AILD. We have described in this report an AML patient who subsequently developed AILD 4 months after the start of induction chemotherapy for AML. During a prolonged leukopenic period, our patient suffered from pericarditis with massive pericardial effusion. We were also puzzled by the persistent fever and subsequently by the appearance of atypical skin rash. Diagnosis of AILD from a lymph node biopsy performed after the appearance of generalized lymphadenopathy urged us to search for the presence of human herpesviruses. Out of human herpesviruses tested, HHV-6 DNA was found in the pericardial effusion, while the leukemic cells were negative
Figure 2
Detection of HHV-6 DNA by PCR. PCR amplification for HHV-6. HHV-6 DNA sequences were also detected not products of HHV-6-specific DNA sequences in extracted DNA were only in the lymph node wih histologic diagnosis of AILD but subjected to electrophoresis and visualized in an ethidium bromidealso in all of the involved organs tested. emergence of AILD. The unusual clinical course suggests that the immunosuppression associated with hematopoietic malignegative in all samples tested (data not shown). In these nancy and the additional iatrogenic immunosuppression folexperiments, we used MT-4 cells infected with HHV-6B strain lowing chemotherapy predisposed the patient to reactivated as a positive control. 26 To monitor contamination, the HHV-HHV-6 infection. Although it is not possible to rule out that 6-free Akata cells 27 were always matched with each sample detection of HHV-6 DNA represents mere passengers in AILD throughout the experiments from DNA extraction to PCR.
lesions, the sequential detection of this virus before and after In order to identify the HHV-6 variant by PCR, we used manifestation of AILD may suggest that HHV-6 infection primer pair 2 covering sites of the immediate-early gene that could directly or indirectly trigger AILD. Episodes of skin rash, flanked a region deleted in variant A, such that the resulting fever, and bone marrow suppression observed in this patient fragments were of different sizes. 24 Amplification with the pricould also be explained by HHV-6 infection. 15, 28 As far as we mers resulted in generation of a 553-bp fragment, indicating are aware, this is the first time that such a sequence of events that the infecting virus was HHV-6 variant B (Figure 3) . has been reported. HHV-6 infection in this patient was found to be due to variant B. Although the relative prevalence of HHV-6A and HHVDiscussion 6B infections in patients with AILD has not been analyzed extensively, our observation is consistent with the report that AILD is a clinicopathological entity first recognized in the HHV-6 variant B has been the most frequently isolated submid-1970s. 16, 17 Although abundant studies for understanding type in immunocompromised patients. 14, 29 Identification of morphological, phenotypic, and genetic features of AILD have the sites and cell types of HHV-6B infection in vivo, which been performed, the etiology of the disease is still obscure. It remains to be elucidated, would shed more light on HHV-6-is well known that patients with AILD have a profound associated AILD. immunologic deficiency. A role of viral infection on triggering In summary, this study provides additional evidence this disorder has been proposed. Luppi et al 21 reported the implicating HHV-6 as a possible cause in some cases of AILD. presence of HHV-6 DNA sequences in archival lymph node Immunocompromised patients may be at particular risk for the tissues from patients with AILD and suggested a possible reactivated HHV-6 infection. Since HHV-6 is susceptible to involvement of this virus in the pathogenesis of some cases of available antiviral agents such as ganciclovir and acyclovir, 30,31 administration of these agents should be considered in the diagnostic evaluation of immunocompromised patients with unexplained fever, atypical skin rash, and generalized lymphadenopathy, as seen in our patient. weighed 6.75 kg (at the 10-25th percentile) and her height Keywords: acute myelocytic leukemia; acute megakaryocytic was 70 cm (at the 75th percentile). There was no evidence of leukemia; methotrexate; polyglutamylation mental retardation or stigmata of Down's syndrome. The patient was pale and had a fever of 101°F. She had moderate hepatosplenomegaly without lymphadenopathy. A 3/6 systolic ejection murmur was recognized at the left sternal border Introduction and ecchymoses were seen over the lower extremities. A complete blood count showed severe anemia and thrombocytopenia (hemoglobin of 3.1 g/dl and platelet count of 8000 per Acute megakaryocytic leukemia is a rare form of leukemia that mm 3 ), and marked leukocytosis with a white blood cell count accounts for 7-10% of pediatric acute myelocytic leukemia of 40 600 per mm 3 , with 40% blasts on the peripheral smear. (AML) cases and has been associated with Down's syndrome Further laboratory analysis was remarkable for elevation of and acute myelofibrosis. [1] [2] [3] [4] It is classified as M7 subtype of lactate dehydrogenase (856 IU/ml). Coagulation studies were AML according to the French-American-British (FAB) classiwithin normal limits. A chest X-ray was normal. Bone marrow fication. 5 Methotrexate (MTX) produced low complete examination revealed hypercellular marrow filled with blasts response rates as a single agent in early clinical trials on AML (93% of total cells) with reticulated chromatin and varying patients (less than 15%) and, in contrast to its importance for amount of cytoplasm. Some blasts had cytoplasmic blebs the treatment of acute lymphocytic leukemia (ALL), it has a and irregular cytoplasmic projections (characteristic of limited role in the current therapeutic management of AML. [6] [7] [8] [9] megakaryoblasts) and others had small indented nuclei. SevImpaired MTX polyglutamylation leading to decreased intraeral blasts were binucleated. Megakaryocytes were markedly cellular retention of MTX is the major mechanism of intrinsic decreased. Cytochemical studies were as follows: periodic resistance to MTX demonstrated in AML blasts (compared to acid-Schiff 8% granular positivity, myeloperoxidase 2% posipre-B ALL blasts) and may explain the observed clinical resisttive, nonspecific esterase negative, and Sudan black negative. ance. [7] [8] [9] [10] However, there is evidence that blasts of acute monImmunophenotyping showed blasts positive for CD34 (85%), ocytic leukemia, M5 AML subtype according to FAB, have CD33 (97%), CD56 (98%), CD61 (64%), CD19 (73%) and higher levels of MTX polyglutamylation (about equal to pre-B CD13 (81%). Blasts were negative for all other antigens tested, ALL blasts) and it has been suggested that patients suffering including CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD11b, from this AML subtype might benefit from MTX. 8 CD10, CD15, CD20 and HLA-DR. Based on the above morWe now report that blasts from two pediatric patients with phologic, histochemical and immunophenotyping characteracute megakaryocytic leukemia (M7-AML) also show istics a diagnosis of M7-AML was made. Cytogenetics of the increased MTX polyglutamylation. Thus M7-AML, like the M5 blasts showed: 46, XX, −6, +der (6) t (6; ?) (p25; ?) in 30% of subtype, may benefit from MTX treatment.
References
the population, and 46, XX, −12, +der (12) t (12; ?) (q; ?) in 70%. Spinal fluid examination was normal.
The patient was initially treated according to a modified BFM/AML 83 protocol 11 with cytosine arabinoside, daunorubicin and etoposide, but failed to attain remission. MTX was given intrathecally on day 1. She was subsequently treated with high-dose cytosine arabinoside and mitoxantrone with The course was complicated by significant weight loss requir-ing the initiation of total parenteral nutrition and by episodes characteristics of megakaryocytes, and moderate to marked diffuse fibrosis. In immunophenotyping, blasts were positive of gastrointestinal bleeding from an unidentified source.
The patient was referred to this hospital at 11.5 months of for CD38 (78%), CD7 (74%), CD34 (72%), CD45 (89%), CD11b (62%), CD61 (30%), HLA-DR (26%) and CD33 (23%). age (4.5 months after diagnosis) for treatment of refractory leukemia. A bone marrow sample was obtained at this time and Karyotype analysis of the blasts showed monosomy of chromosome 7: 45, X, der(Y) t(Y;1) (q12;q21), −7. Based on the tested for polyglutamylation of MTX. She received modified NY II induction chemotherapy, 12 with idarubicin (instead of above a diagnosis of M7-AML with acute myelofibrosis and myelodysplastic features was made. Bone marrow was daunomycin), cyclophosphamide, vincristine and asparaginase, which was complicated by neutropenia and gram-negaobtained at this time and tested for MTX polyglutamylation.
The patient was treated with sequential experimental thertive sepsis. The patient remained febrile with multiple negative repeat blood cultures despite the administration of apies; 2-chlorodeoxyadenosine, R 24 monoclonal antibodies and subsequently taxol, without response. His course was ceftazidime, gentamicin, vancomycin and amphotericin-B and her persistent fever was attributed to leukemia itself. Subcomplicated by fever, neutropenia, and gastrointestinal symptoms from typhlitis. A palliative trial of ifosfamide and etoposequently she received taxol (phase I protocol, CCG-0903) and then vinorelbine (phase I protocol, CCG-0936) without side had no effect. The patient expired 13 months after diagnosis. response. The patient expired at the age of 14.5 months (7.5 months after diagnosis).
Materials and methods

Case 2
Heparinized bone marrow was obtained from both patients after obtaining informed consent. Both patients were refracAn 18-year-old Norwegian male with no significant past medical history presented with a 2-month history of easily tory to chemotherapy at the time of specimen collection, but were methotrexate naive (except the administration of one bruising and fatigue at another hospital. Family history was significant for prostate cancer and endometrial cancer in the dose of MTX intrathecally). Cells were separated with a standard Ficoll-Hypaque density gradient centrifugation, washed maternal grandfather and grandmother, respectively. There was no history of exposure to carcinogens. On physical examwith PBS, and resuspended in RPMI-1640 with 10% FBS, as previously performed. [8] [9] [10] The polyglutamylation assay was ination he was pale with few ecchymoses over the upper extremities. No organomegaly or lymphadenopathy was performed as described earlier. [8] [9] [10] Briefly, after 24-h incubation of 2 × 10 7 blast cells with 10 mM 3 H-MTX in RPMIdetected. A complete blood count revealed a hemoglobin of 4.5 g/dl, platelet count of 15 000 per mm 3 and white blood 1640 with 10% dialyzed FBS at 37°C and 5% CO 2 atmosphere the cells were washed with cold PBS twice and subcell count of 12 100 per mm 3 . The peripheral blood smear showed 50% blasts with scanty cytoplasm. There were 10% sequently lysed by boiling in NaH 2 PO 4 buffer (50 mM, pH 5.5). The supernatant was stored at −20°C until the total neutrophil stabs and granulocytes of which 1/3 were pseudoPelger Huet forms. Cytochemistry of the blasts was negative MTX and MTX polyglutamates (in pmol per 10 7 cells) were measured in batches by quantitating the radioactivity in a for myeloperoxidase and low positive for lysozyme. Immunophenotyping of the peripheral blood blasts showed positivity liquid scintillation counter (Beckman LS5801; Beckman, Palo Alto, CA, USA) after HPLC analysis. 9 for CD34 (84%), CD7 (87%), CD3 (89%) and CD33 (30%), but failed to demonstrate megakaryocytic, myeloid, monocytic, or erythroid markers. Bone marrow aspiration gave a 'dry tap', however, bone marrow biopsy revealed fibrosis with Results and discussion atypical megakaryocytes.
The patient was initially thought to have T cell ALL and was The results are summarized in Table 1 . Values of total as well as long chain MTX polyglutamates from assays performed prestarted on chemotherapy with vincristine, prednisone, asparaginase, doxorubicin and cyclophosphamide, without viously in AML (43 patients with M1-M4 and eight patients with M5 subtype) and ALL (34 patients with pre-B ALL) blasts response. He also received a dose of MTX intrathecally. On re-evaluation a probable M7-AML diagnosis was made and the patient received a cycle of cytosine arabinoside, daunoru- Table 1 Comparison of total and long chain MTX polyglutamate bicin and 6-thioguanine, after which he developed a proamounts in M7-AML and other AML subtypes, and ALL longed aplastic period. A repeat bone marrow examination showed less than 5% blasts. Chemotherapy was continued increase in immature myeloid cells, some of which had in our laboratory using the same method [8] [9] [10] are also displayed mon finding in intrinsically resistant to MTX neoplasms such as AML, adult ALL, soft tissue sarcoma and cervical carcinoma for comparison. M7-AML cases showed significantly higher amounts of total MTX and MTX polyglutamates than M1-M4 cells. [7] [8] [9] [10] Moreover, decreased accumulation of total MTX and MTX polyglutamates has been correlated with poor prognosis subtypes of AML, and were comparable to M5 subtype and pre-B ALL. The amounts of long chain (glu [3] [4] [5] [6] ) MTX polyglutain some children with ALL. 18 Goker et al 8 have reported previously that acute monocytic leukemia (M5) blasts accumulate mates were also significantly greater in M7-AML blasts compared to M1-M4 subtypes of AML, and were approximately significant amounts of total and long chain polyglutamates. THP-1, an AML cell line of the M5 subtype, was shown to equal to the amounts accumulated in pre-B ALL blasts.
AML subtypes are classified on the basis of morphologic, have near equivalent MTX polyglutamate accumulation as ALL cell lines and this was associated with sensitivity to MTX cytochemical and immunophenotyping criteria but can also differ in their clinical presentation, response to therapy, manin cytotoxicity assays. 8 The present report demonstrates that the two M7-AML patients studied had blasts that were capable agement and prognosis. M7-AML was initially considered an undifferentiated variant of AML (Sudan black or myeloperoxiof accumulating significant amounts of total as well as long chain MTX polyglutamates. This result was not directly condase negative) and only in 1985 were the criteria for its diagnosis established by FAB. 5 For its diagnosis and differentiation firmed by cytotoxicity assays because of the difficulties of performing in vitro assays of antimetabolites on leukemic blasts from ALL the demonstration of an immunophenotype with antigens characteristic of megakaryocytic lineage such as obtained from patients because of their lack of growth in cell culture. CD41 (glycoprotein IIb/IIIa), CD42b (glycoprotein Ib) or CD61 (glycoprotein IIIa), or platelet peroxidase activity on electron M7-AML is considered to be poorly responsive to chemotherapy and to have a poor prognosis, as was observed in our microscopy is required. [1] [2] [3] [4] [5] 13 CD61 has been reported as more sensitive than other platelet markers to detect immature cells cases. [1] [2] [3] [4] 19 However, there have been reports of long remissions in pediatric patients. 3, 19 Moreover, patients with of megakaryocytic origin and was used to document megakaryocytic origin in our cases (at least 30% positivity in both M7-AML and Down's syndrome were shown to respond well to chemotherapy and to have a favorable prognosis. 15 Owing cases). 2, 14 Our diagnostic criteria were in accordance with criteria used previously. [1] [2] [3] [4] [5] to the rarity of M7-AML, data on its appropriate management are usually extrapolated from data from clinical series that M7-AML has two peaks in its distribution of incidence, one in adults and the other in young children. 3 Most of the pedistudied AML as a whole. Not surprisingly we have been unable to document any clinical studies on the effect of MTX atric cases occur in children less than 3 years of age. 3, 4 The clinical presentation in children includes anemia, thrombocyin M7-AML. Both of our patients were refractory to other chemotherapy when the polyglutamylation assays were pertopenia, leukocytosis (or leukopenia in cases associated with myelofibrosis) and organomegaly, while in adults with de formed, but did not receive MTX in their course of illness, except for one dose of intrathecal administration because novo M7-AML organomegaly is not a constant feature. [2] [3] [4] Ultrastructural analysis showed that blasts from children with these data only became available postmortem. Our findings of relatively increased MTX polyglutamylation in M7-AML blasts M7-AML are more immature than those from adults with M7-AML. 3 Acute myelofibrosis (evident in case 2) has been assosuggests that M7-AML blasts may be sensitive to MTX and MTX needs to be considered earlier in the treatment of this ciated with M7-AML mainly in adults, but also in pediatric cases, 1,2 and has been attributed to fibroblast growth factors illness. Whether this is a consistent feature of M7-AML will require the study of more patient samples which will necessisynthesized by megakaryoblasts.
2 M7-AML is the commonest type of AML that develops in Down's syndrome. 15 Some of tate the cooperation of multiple institutions as this condition is extremely rare. Owing to the rarity of this leukemia subtype those cases occur in association with myelodysplasia. 15 Dysmegakaryocytopoiesis has been reported in a variety of AML and the possibility that MTX may be useful for the treatment of patients with M7-AML we have reported our results in these subtypes and was recognized in case 2. 16 A broad range of blast karyotype abnormalities has been two patients. described in M7-AML. Of interest is the frequently observed translocation t(1;22) in infants with M7-AML as well as abnormalities of chromosome 21 (constitutional or acquired).
4,17
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LETTERS TO THE EDITOR Normal G-CSF-mobilized CD34
+ peripheral blood stem cells in paroxysmal nocturnal hemoglobinuria: a perspective for autologous transplantation
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired
Very low levels of CD34 + PBSC (less than 0.04%) were detected before G-CSF treatment (Table 1) . However, after 5 genetic disorder resulting from the expansion of a clone (or clones) that arises by a somatic mutation occurring in the Xdays of G-CSF, the three patients mobilized a number of CD34 PBSC, enough for a cytofluorimetric analysis. The prolinked PIG-A gene and involving a pluripotent hematopoietic stem cell. [1] [2] [3] [4] Cells of abnormal clones are deficient in all those portional and absolute levels of CD34 + PBSC ranged from 0.05 to 0.4%, and from 7.5 to 41.2/l, respectively (Table 1) . plasma membrane proteins that, in normal subjects, are anchored by a glycosyl-phosphatidyl-inositol (GPI) molecule,
In contrast to non-PNH patients, most of these mobilized CD34 + PBSC did not express the CD59 antigen, thus suggestwhose biochemical synthesis, initially regulated by the PIG-A gene, is altered in PNH patients. 4, 5 The demonstration of the ing that the majority of them belonged to the mutated PNH clone (Figure 1 ). However, a variable proportion (13.4-absence of such GPI-linked proteins on circulating blood cells is now widely used as a diagnostic test for PNH, which pro-40.3%) showed an apparently normal phenotype, co-expressing both CD34 and the GPI-linked antigen CD59 (Figure 1 ). vides a specific marker for distinguishing affected from normal cells. 6, 7 Peripheral blood stem cells (PBSC), usually identified No significant adverse effects due to G-CSF were recorded during and immediately after the study. by their positivity for CD34 antigen and obtained in large amounts by mobilizing chemotherapy and/or growth factor Thus, we demonstrated the presence of CD34 + PBSC in PNH patients stimulated with G-CSF. More interestingly, a sigadministration, are extensively used as a source of autologous hematopoietic precursors for transplantation in several hemanificant proportion of these cells were, at least cytometrically, not involved in the mutated clone since they normally tologic disorders. The aim of the present study was to verify the presence of circulating normal hematopoietic precursors expressed the GPI-linked molecule CD59. Recently, similar findings have been observed in leukaphereses from unstimuin PNH, as a possible first step in the therapeutic perspective of autologous PBSC transplantation for these patients.
lated PNH subjects. 9 The present analysis is the first study to report a phenotypic evaluation of CD34 + PBSC achieved in We analyzed, by means of a double labeling cytofluorimetric assay, the presence of the GPI-linked molecule CD59
PNH patients receiving G-CSF in vivo. PNH patients released variable yields of normal PBSC. It remains to be defined (a membrane inhibitor of reactive lysis or MIRL) on CD34 + PBSC from three PNH patients (one male and two females, whether this reflects different proportions of non-clonal residual hematopoiesis, a fact that could have prognostic sig-20-44 years old), mobilized by in vivo administration of G-CSF (Neupogen, Dompé-Biotec, or Granulokine, Roche, nificance for the heterogeneous population of PNH patients. 10 In the clinical setting, the combination of leukapheresis 9 Milan, Italy; 300 g/day s.c. for 5 days). CD59 was selected from among various other GPI-linked molecules, since it was and administration of G-CSF could be a feasible approach to achieving a larger number of CD34 + PBSC in PNH patients. constantly expressed on 99-100% of CD34 + PBSC detected in 10 leukaphereses we performed after mobilizing chemoThe adjunct of selective ex vivo expansion 11 of 'pure' CD34 + /CD59 + PBSC, could significantly increase the number therapy plus G-CSF in patients with neoplastic hematological disorders, which served as controls. All patients gave written of normal hematopoietic precursors potentially available, in the so far unexplored therapeutic perspective of an autologous informed consent for the entire procedure. Two of them have been previously reported among the first Italian examples of PBSC transplant in these patients. In the light of the so-called 'selective pressure hypothesis', according to which GPI-PIG-A gene mutations in PNH. 8 In brief, 100 l of whole mobilized peripheral blood were deficient cells are allowed to grow while normal cells are inhibited by immunological mechanisms, 3, 12 autologous simultaneously incubated at 4°C in the dark for 25 min with 10 l phycoerythrin or fluorescein-isothiocyanate-labeled transplantation of PBSC could permit a 'maximal' immunosuppression. A possible effect on the harmless PNH clone, monoclonal antibodies recognizing, respectively, CD34 (HPCA2, Becton Dickinson, San José, CA, USA) and CD59 however, should also be considered. Molecular studies are in progress in order to confirm the absence of PIG-A gene (CBL467, Cymbus Bio-Science, Alma Research, Firenze, Italy). After red blood cell lysing and washing twice by centrifugmutations in PNH CD34 + /CD59 + cells. ation in phosphate-buffered saline, the data were acquired on a FACSort flow cytometer (Becton Dickinson) equipped with a 15-mW argon laser emitting at 488 nm and Lysis II software. All channels were set for acquisition in the logarithmic mode. An initial acquisition gate was set according to side light scat- Table 1 Proportional and absolute values of CD34 + PBSC in three ter and orange fluorescence intensity, in order to collect only 
Italy
In the September 1996 issue of Leukemia, we commented on and incidentally, mice do not have an expressed homologue of the HLA-DP locus. a paper by Taylor et al previously published in the journal. 1, 2 Our main concern was the lack of statistical evaluation. In a Also in childhood ALL, we did not find a significant increase in the genotype frequencies in the whole group of following issue, a reply by two of the authors was published, 3 in which instead of replying to the main criticism on the lack 63 patients (17.5 vs 13.6%). 6 However, the homozygosity rates were different between boys and girls (27.7 vs 3.7%, of any significant increase in their report, Gokhale and Taylor chose to attempt to invalidate our unpublished results in P = 0.01) yielding a relative risk of 3.29 (95%, CI = 1.37-7.90) for boys homozygous for DR53 to develop common ALL (33.3 Hodgkin's disease as well as our previous findings in other hemopoietic malignancies.
vs 13 .6%, P = 0.008). These findings have now been confirmed in an updated group of 84 patients. 11 Based on the Dorak et al are still persuaded that homozygosity for HLA-DR53 is the most consistent association in hemopoietic maligmolecular mimicry between HLA-DR53 antigen and viral proteins, 12 and this gender effect, we have been able to propose nancies as it has been shown in three leukemias (CML, ALL, CLL) in three different populations by molecular analysis. [4] [5] [6] a model which might be relevant in the development (not etiology) of childhood ALL. 13 Also in AML, an HLA-DR53 association was noted in a study that used a specific monoclonal antibody. 7 In CLL, an HLAHomozygosity for HLA-DR53 precisely means homozygosity for the HLA-DRB4‫10ء‬ allele therefore mapping the suscep-DR53 association was previously reported in another British study. 8 In the first molecular HLA association study on leuketibility around the DRB4 locus. We did check the relevance of the HLA-DRB1 locus by scientific methods both in CML mia, we typed 112 patients and 432 local controls at 10 MHC loci to have a holistic view of the HLA complex and to avoid and CLL and did not find a stronger association with it. There is no reason to discuss the meaning of heterozygosity for spurious associations due to linkage disequilibrium. 4 By conventional analysis, there was no difference in the homozygos-DRB1 alleles as it is not the susceptibility locus. As discussed above there is enough reason to believe HLA-DR53 is the susity rates between patients and local controls (11.6 vs 13.4%, respectively). Most researchers in this field would have conceptibility allele in hemopoietic malignancies and this association may be HVR sequence-related. The seven consecutive cluded a lack of association. However, the oldest patient homozygous for HLA-DR53 was 52 years old (P = 0.004), and amino acids (LLERRRA) of the HVR3-encoded immunodominant epitope of HLA-DR53 is mimicked by pathogenic viruses the homozygosity rates in patients below and above the median age were different (25.7 vs 5.2%, P = 0.003). The including EBV which plays a role in the pathogenesis of Hodgkin's disease. 12 For this reason and also to investigate the role study on CLL further confirmed the influence of the DR53 homozygosity (corresponding figures being 18.6 vs 2.9%, of HLA-DR53 in another hemopoietic malignancy, we initiated a study on Hodgkin's disease. As clearly stated in our P = 0.03), and also showed the protective (delaying) effect of homozygosity for HLA-DR52. 6 The mean ages of patients with original communication, we only have 'preliminary data' that appeared as an 'abstract'. We have reported that in the class II CLL homozygous for DR53 and DR52 are 54.8 ± s.e. 3.7 vs 65.8 ± s.e. 2.8 years (P = 0.02; two-tailed t-test), respectively. region, there was no significant association even with the early-onset group. A detailed analysis of the patients homoThe corresponding figures in the CML group are 32.1 ± s.e. 3.1 vs 49.4 ± s.e. 5.0 years (P = 0.007). The overall age distrizygous for HLA-DR53 showed that seven of the eight patients with this genotype were under the median age (P = 0.06) and butions of these two groups of patients are also significantly different by the log-rank test both in CLL (P = 0.04) and CML the oldest patient homozygous for DR53 was 46 years old (P = 0.04). We now have more samples and are still collecting (P = 0.01). These significant observations are strikingly similar to those made by Lilly et al 9 in their original study on mice. consecutive patients' samples. The results will be presented when the study is complete. In a congenic mouse model, they showed the influence of the two homozygous genotypes (namely H-2 k and H-2 b ) on the We will not be surprised if Hodgkin's disease has the same association with HLA as other major hemopoietic maligrate of development of both virus-induced and spontaneous leukemia. Unlike homozygosity, heterozygosity for H-2 k did nancies despite their very different etiologies. Because HLA has no primary role in the etiology of these diseases, a certain not accelerate the development of leukemia. It has to be noted that H-2 k and HLA-DR53 are serologically cross-reactive, 10 HLA genotype may be 'associated' with more than one disease. This is not speculation but a simple fact repeatedly shown in different studies. This is no different from the well- ance with Johansson's results. Moreover these secondary aberInterferon has the potential to induce lasting complete or rations involved largely chromosome 3 (five cases), 9 (two major cytogenetic remissions in 20 to 30% of patients with cases) and 18 (two cases) associated with chromosome Ph1 chronic-phase Ph1-positive CML and has prompted a large and occurred in two patients in chronic phase. The analysis number of clinical trials. Cytogenetic response increased the of data from Johansson et al and our own shows a high inciduration of chronic phase and survival of the responding dence of cytogenetic alterations of chromosome 3 (11 cases patients. 2 Despite limited knowledge regarding the pharmacoover 42). Most of these concerned the long arm between q21 logic mechanisms by which IFN induces the unpredictable and q27 which is the locus of genes involved in leukemogencytogenetic response in CML, this therapy becomes standard esis such as the ecotropic virus integration 1 gene in acute therapy for patients with newly diagnosed CML. However, myeloid leukemia and myelodysplasia. We hypothesize that interferon produces side-effects that are usually dose-depen-IFN directly or indirectly induces a specific break on the long dent, such as flu-like symptoms, persistent fatigue, weight loss, arm of chromosome 3. However, what is the importance of depression and insomnia. Moreover, interferon-␣ can produce dose and duration of treatment with IFN? Some cytogenetic aberrations such as del (5), del(7), del(9) or −X are noted in myelodysplasia and suggest such an evol-leukemia treated with interferon-␣. Leukemia 1996; 10: 1134-growth-regulating cytokines and receptors. 4 Recently, Beelen 
Enhancement of mdr1 gene expression by transforming growth factor-␤1 in the new adriamycin-resistant human leukemia cell line ME-F 2 /ADM
Multidrug resistance (MDR) of tumor cells is a major problem increased in ME-F 2 /ADM100 and ME-F 2 /ADM200 cells in proportion to their respective level of drug resistance. in the treatment of cancer. The MDR phenotype is closely associated with overexpression of the mdr1 gene and its proWe examined whether cytokines could modulate the P-gp expression on ME-F 2 /ADM100 and ME-F 2 /ADM200 cells. The duct, P-glycoprotein (P-gp), which functions as an efflux pump preventing the intracellular accumulation of structurally unrecells (1 × 10 6 ) were incubated with the following cytokines at optimal concentration: IL-3 (100 U/ml), IL-4 (100 U/ml), IL-6 lated drugs. [1] [2] [3] [4] The levels of mdr1 mRNA and P-gp have been reported to be regulated by cytokines 5, 6 and various other (100 ng/ml), granulocyte colony-stimulating factor (100 U/ml), stem cell factor (100 ng/ml), erythropoietin (100 U/ml), interagents such as steroid hormone 7 and differentiating agents. 8 In the present study, we established adriamycin (ADM)-resistant feron-␥ (100 U/ml), leukemia inhibitory factor (1000 U/ml) and TGF-␤1 (10 U/ml) in 2 ml of medium for 24 h. TGF-␤1 sublines which expressed highly the mdr1 gene and P-gp, and demonstrated for the first time that this expression was increased markedly the P-gp expression on ME-F 2 /ADM100 and ME-F 2 /ADM200 cells, although none of the cytokines, increased by transforming growth factor (TGF)-␤1.
We selected two ADM-resistant sublines, ME-F 2 /ADM100 except for TGF-␤1, modulated the P-gp expression. Next we analyzed the effect of TGF-␤1 on the expression of mdr1 gene and ME-F 2 /ADM200 which could stably proliferate in 100 ng/ml and 200 ng/ml of ADM, respectively, from a human in ME-F 2 and ME-F 2 /ADM100 cells. As shown in Figure 1a , TGF-␤1 increased the expression of mdr1 gene in MEmyelomonocytic leukemia cell line, ME-F 2 , 9 by continuous exposure to a step-wise increase in the concentration of ADM. F 2 /ADM100 cells within 1 h, and the level was maintained for a further 24 h. By contrast, TGF-␤1 did not affect the ME-F 2 /ADM100 and ME-F 2 /ADM200 cells had a cross-resistance to daunorubicin and vincristine which was reversed by expression of mdr1 gene in ME-F 2 . This suggests that TGF-␤1 affects the mdr1 gene expression as an early effect in MEverapamil. The expression of the mdr1 gene and P-gp in parental ME-F 2 , ME-F 2 /ADM100 and ME-F 2 /ADM200 was ana-F 2 /ADM100 cells. Recent studies reported that protein kinase C (PKC)-mediated the activity of TGF-␤ signaling pathways lyzed by RT-PCR and flow cytometric analysis with the monoclonal antibody MRK16 (Kyowa Medex, Tokyo, Japan) as that lead to the activation of gene transcription. 12, 13 To elucidate the relationship between PKC and TGF-␤1 signaling described previously. 10 The primer sets of mdr1 and ␤ 2 -microglobulin (␤ 2 m) were chosen by Noonan et al. 11 Amplipathway, we further analyzed whether sphingosine, a specific PKC inhibitor, could inhibit the effect of TGF-␤1 on the fication was performed in a thermal cycler for 20 cycles (1 min at 94°C, 1 min at 55°C, and 1 min at 72°C). Neither expression of mdr1 gene in ME-F 2 and ME-F 2 /ADM100 cells. As shown in Figure 1b , the mdr1 gene expression in ME-PCR product of mdr1 nor P-gp expression were detected in ME-F 2 . However, the expression of mdr1 gene and P-gp was F 2 /ADM100 cells cotreated with sphingosine and TGF-␤1 was decreased to near the level of mdr1 expression in the nontreated ME-F 2 /ADM100 cells. This result shows that increase related signal transduction pathway in ME-F 2 /ADM100 cells.
we showed that TGF-␤1 itself could induce the mdr1 gene expression as an early effect without cell transformation. Although the role of TGF-␤1 in the drug-resistance phenotype is unclear, TGF-␤1 may contribute to malignant progression by promoting the acquisition of drug resistance.
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